Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Follow-up of Priorix-Tetra vs Separate Priorix and Varilrix
NCT00406211Phase 3Completed
- Sponsor
- GSK
- Start
- Jul 2004
- Primary completion
- Dec 2004
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of GSK208136 in measles, mumps, rubella and 1 more (2 arms), sponsored by GSK. Primary endpoints: Seropositivity rate for MMRV antibodies at 3 years, Antibody titers for MMRV at 3 years and 1 more. Started Jul 2004; status: completed.
02
Drugs
GSK208136
03
Conditions
measlesmumpsrubellavaricella (VZV)
Beyond the preview
Go deeper on NCT00406211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00406211.